Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s stock price dropped 4% during trading on Thursday . The company traded as low as $16.81 and last traded at $16.85. Approximately 73,147 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 186,510 shares. The stock had previously closed at $17.56.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.
Check Out Our Latest Analysis on Pulse Biosciences
Pulse Biosciences Stock Up 4.8%
The business's 50 day moving average is $16.85 and its 200 day moving average is $18.00.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after purchasing an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Pulse Biosciences during the fourth quarter worth about $44,000. AlphaQuest LLC grew its stake in shares of Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock worth $50,000 after acquiring an additional 1,261 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences during the first quarter valued at about $90,000. Finally, Caisse Des Depots ET Consignations purchased a new position in shares of Pulse Biosciences in the 4th quarter valued at approximately $95,000. 76.95% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
